| Unsubscribe |
Below is an important message from one of our highly valued sponsors. Please read it carefully as they have some special information to share with you.
Dear Reader,
Jeff Bezos is terrified.
He will be down on his knees, hands out, begging Elon for mercy.
Because Elon is about to do something that will:
Cut Amazon out of the AI race ENTIRELY…
Completely DESTROY Blue Origin…
And take control of the potential $25 TRILLION DOLLAR PER YEAR AI INDUSTRY
And in his wake, potentially create 1,806,000 NEW millionaires over the coming years…
Starting September 25.
And this is your chance to be one of them.
Elon Musk is currently quietly planning the biggest project of his entire career.
And a single FCC filing proves it, click here to see why.
This is bigger than Tesla, SpaceX, and X combined.
And I believe it will not only cement Elon as the winner of the AI race…
It will allow Elon to control the entire industry.
Something of this magnitude has never happened in the history of the human race.
And it’s happening FAST.
According to my timeline, you must act by September 25.
I explain everything right here.
>>>This is your free Millionaire Maker Masterclass… and it starts right now.
Sincerely,
James Altucher
P.S. I am giving away a gift worth $1,000 to the first 1,000 people who watch and take action on my Masterclass offer today. No purchase necessary. ZERO credit card required. Just click here to watch my free video, and I’ll show you how to claim yours.
3 ETFs Built to Protect Your Money if the Bull Market Breaks
By Nathan Reiff. Date Posted: 8/17/2026.
Key Points
- Buffered ETFs use options strategies to cap both losses and gains over set periods, offering an alternative to traditional 60/40 portfolio allocations amid an aging bull market.
- PJUL, one of the largest and oldest buffered ETFs with $1.3 billion in assets, protects against the first 15% of S&P 500 losses while capping gains near 14%.
- BSEP offers less downside protection than PJUL but a slightly higher cap, while QBUF tracks the Nasdaq-100 with quarterly resets and a lower 5.97% upside cap.
- Special Report: The company SpaceX cannot operate without
Almost four years in, and despite countless challenges, the bull market is still going, presenting investors with a familiar dilemma: Should they try to capture additional equity gains as the market continues to rise, or take steps to protect against a potential pullback, potentially giving up some of those returns? This balancing act has driven investors to look to a lesser-known corner of the exchange-traded fund (ETF) space: buffered ETFs, which aim to limit downside losses while still providing exposure to at least some upside.
Buffered ETFs have surged as an alternative to a traditional 60/40 approach to portfolio construction. These ETFs use options strategies to establish a certain level of downside protection over a specified period. While investors will need to determine whether buffered ETFs fit their individual risk tolerances, the Innovator U.S. Equity Power Buffer ETF – July (BATS: PJUL), the Innovator U.S. Equity Buffer ETF – September (BATS: BSEP), and the Innovator Nasdaq-100 10 Buffer ETF (BATS: QBUF) provide three different entry points into the space, along with a variety of options in terms of downside protection and upside potential.
PJUL Is a Buffered ETF Stalwart With High Levels of Protection
ALERT: Drop these 5 stocks before the market opens tomorrow! (Ad)
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings.
Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds.
If any of these are in your portfolio, now is the time to review your positions.
See the 5 stocks to avoidPJUL is one of the oldest buffered ETFs, having launched in 2018, and is also one of the largest, with approximately $1.3 billion in managed assets. The fund aims to track the return of the SPDR S&P 500 ETF Trust (NYSEARCA: SPY), representing the broader S&P 500 Index, while protecting against the first 15% of losses. Investors should note that the fund's starting cap, before its 0.79% annual fee, is 13.98%, which is about 1% above the S&P's current year-to-date (YTD) return.
While other buffered funds provide more robust protection, PJUL strikes a healthy balance between downside protection and capped potential gains, allowing investors to capture solid market growth.
This makes it an excellent choice for investors seeking some protection but unwilling to give up too much potential return in exchange. However, investors should note that the fund's predetermined outcome period runs from July 1 through June 30. Those who buy after July 1 may not realize the fund's intended outcome.
Unless an investor is willing to wait until July 2027 to buy in, they should be aware of the potential for results to deviate from the fund's stated outcomes if they do not follow the defined outcome period.
BSEP Takes on More Risk
BSEP functions similarly to PJUL in many ways: It also tracks the SPY and uses options to cap both potential upside and downside. An important distinction, however, is that BSEP has a slightly higher risk level. The fund protects against the first 9% of losses, less than PJUL. In exchange, BSEP has a modestly higher upside cap of 15.35% before annual fees, which are the same as PJUL's.
The trade-off may not seem worthwhile: BSEP gives up 6% of loss protection in exchange for less than 1.5% of additional gain potential. This could be part of the reason why the fund's asset base is only around $216 million, a fraction of PJUL's. However, because BSEP's defined outcome period runs from Sept. 1 to Aug. 31 each year, investors considering buffered ETFs over the summer have the opportunity to buy in and hold shares of BSEP throughout the full outcome period without having to wait until the following year.
QBUF Trades SPY for Nasdaq Exposure
Tech stocks have driven much of the broader market rally, and QBUF takes a buffered approach to the tech-centric Nasdaq-100 Index. By tracking the return of the Invesco QQQ Trust (NASDAQ: QQQ), QBUF is positioned to benefit when many of the largest tech stocks trading in the U.S. rise.
The fund distinguishes itself from both of the others not only through its focus but also through its structure. Rather than using a full-year defined outcome period, QBUF resets at the beginning of each new three-month period. This gives investors more opportunities throughout the year to buy in without their investments potentially deviating from QBUF's preset outcomes.
For each period, the fund provides fairly solid downside protection of 10%, which helps cover not only a potential significant decline in tech stocks but also some of the sector's near-term volatility.
The issue for investors, however, may be QBUF's limited upside potential: The fund caps gains at 5.97% before its 0.79% annual fee. This makes QBUF a target for investors interested in tech but willing to make only a cautious bet.
One Platform, Every Ailment: Hinge Health's Gamble
By Chris Markoch. Date Posted: 8/20/2026.
Key Points
- Hinge Health shares have risen 91% in 2026, trading at a roughly 69x P/E ratio as the company expands beyond musculoskeletal care into migraine and gastrointestinal treatment.
- Strong Q2 2026 earnings, including 52% revenue growth and an EPS beat, prompted Hinge to raise its full-year revenue and operating income guidance.
- New ventures like the Cylinder Health acquisition and migraine program offer large addressable markets but contribute only modest near-term revenue, leaving the premium valuation vulnerable to execution missteps.
- Special Report: The company SpaceX cannot operate without
Many people know that seemingly unrelated symptoms can be connected. But in most cases, treating individual symptoms means scheduling a separate doctor visit, sometimes with different specialists, before the full picture emerges. What if it didn’t have to be that way?
That’s the question that Hinge Health (NYSE: HNGE) is attempting to answer. It also explains why HNGE is behaving like a technology stock with a valuation to match. It’s up 91% in 2026 and has a price-to-earnings (P/E) ratio of around 69x. The question for investors is whether it’s better to be early or late.
Hinge’s Future Hinges on Expansion
ALERT: Drop these 5 stocks before the market opens tomorrow! (Ad)
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings.
Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds.
If any of these are in your portfolio, now is the time to review your positions.
See the 5 stocks to avoidHinge Health is known for its AI-powered care platform for musculoskeletal (MSK) conditions. The platform uses smartphone cameras to track anatomical movement in real time. This helps automate the vast majority of clinician hours while improving outcomes for members with back, joint and muscle pain.
But what’s propelling HNGE in 2026 is its expansion beyond MSK. The company is adding a Migraine Care Program and, more significantly, pushing into digestive care through its pending acquisition of Cylinder Health, a virtual-first gastrointestinal care company with an existing footprint of 100 clients, 2 million lives and relationships with three of the top five national health plans.
It's the first step in a bold plan to address multiple conditions through one platform. That has analysts and investors excited. It’s also where the risk lies.
Earnings Show the Runway That Could Lead to a Reward
Hinge Health’s Q2 2026 earnings report stands out in an earnings season that has seen some impressive results. Revenue of $212.82 million was more than 52% higher year over year. Adjusted earnings per share (EPS) of 59 cents beat expectations of 28 cents by more than 100%. The company’s operating margin expanded to 29%, and free cash flow (FCF) rose to $100 million, representing a 47% margin.
Hinge also increased its full-year revenue outlook to a range of $856 million to $860 million. It also raised its forecast for operating income to a range of $236 million to $244 million. The company cited stronger-than-expected enrollment yields as a key reason for its bullish guidance.
That's the reward, but it comes with risk. The risk is what comes next: layering two new, largely unproven verticals onto a business that has just found its financial footing.
The Multi-Condition Bet
Hinge frames its opportunity in three addressable markets: $661 billion in MSK, $78 billion in migraine and $135 billion in gastrointestinal. Stacked together, that's a target market north of $870 billion. To put those numbers into perspective, in the trailing 12 months ending with the company’s Q2 2026 earnings report, Hinge generated around $720 million in revenue.
That ambition is the center of the bull case, but the near-term contribution from the new categories is modest by design. Management expects the Cylinder Health deal, a $105 million cash transaction slated to close later this quarter, to add only $7 million to $8 million of revenue in 2026, with a broader rollout planned for 2027. The migraine program is earlier still, with client approvals in hand but no revenue impact yet broken out.
In other words, investors are being asked to pay up today for optionality that mostly shows up in the numbers a year or two from now. Neither Cylinder nor the migraine program has been confirmed profitable on a standalone basis, and integrating a new clinical category—with different care pathways, partner relationships and reimbursement dynamics—is a harder execution problem than scaling an existing one.
Is Too Much Future Growth Priced Into HNGE?
None of this seems to be spooking the market. The Hinge Health analyst forecasts on MarketBeat give HNGE a consensus price target of $100.57. That consensus price has been climbing over the past four quarters, indicating that analysts continue to rerate the stock.
That’s evident in the stock chart, which briefly reclaimed its 52-week high after the earnings report. An ascending 50-day simple moving average (SMA) acting as support suggests dip-buyers have been in control since the reversal that began in April.
For Hinge to keep growing, investors have to assume the MSK business continues to compound at a high rate while migraine and GI mature into meaningful contributors as scheduled.
But the valuation leaves little room for a stumble. If Cylinder's integration slips, migraine enrollment disappoints or MSK growth simply decelerates as the law of large numbers catches up, a stock priced for perfection tends to react accordingly. That explains why there’s still over 9% short interest in HNGE.
This email is a sponsored email for Paradigm Press, a third-party advertiser of DividendStocks.com and MarketBeat.
If you have questions about your account, feel free to email MarketBeat's South Dakota based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
Copyright 2006-2026 MarketBeat Media, LLC.
345 N Reid Place, Suite 620, Sioux Falls, S.D. 57103-7078. USA..
No comments:
Post a Comment